Publication:
Folic acid-conjugated cationic Ag2S quantum dots for optical imaging and selective doxorubicin delivery to HeLa cells

dc.contributor.coauthorErkısa, Merve
dc.contributor.coauthorArı, Ferda
dc.contributor.coauthorUlukaya, Engin
dc.contributor.departmentDepartment of Chemistry
dc.contributor.departmentGraduate School of Sciences and Engineering
dc.contributor.departmentKUYTAM (Koç University Surface Science and Technology Center)
dc.contributor.kuauthorAcar, Havva Funda Yağcı
dc.contributor.kuauthorDuman, Fatma Demir
dc.contributor.kuauthorKhodadust, Rouhollah
dc.contributor.schoolcollegeinstituteCollege of Sciences
dc.contributor.schoolcollegeinstituteGRADUATE SCHOOL OF SCIENCES AND ENGINEERING
dc.contributor.schoolcollegeinstituteResearch Center
dc.date.accessioned2024-11-10T00:05:15Z
dc.date.issued2017
dc.description.abstractWe aim to develop folic acid ( FA)-conjugated cationic Ag2S near-infrared quantum dots (NIRQDs) for the delivery of doxorubicin (DOX) selectively to folate receptor (FR)-positive cancer cells to achieve enhanced drug efficacy and optical tracking in the NIR region. Materials & methods: Cationic Ag2S NIRQDs were decorated with FA using a PEG bridge and loaded with DOX. In vitro studies were performed on FR-positive human cervical carcinoma cells and FR-negative A549 cells. Results: Significantly higher uptake of DOX by human cervical carcinoma cells cells and a greater therapeutic effect along with a strong intracellular optical signal were obtained with DOX-loaded FA-conjugated Ag2S NIRQDs. Conclusion: These Ag2S NIRQDs are promising theranostic nanoparticles for receptor-mediated delivery of DOX with enhanced drug efficacy combined with optical imaging.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue19
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipScientific and Technological Research Council of Turkey [113Z164]
dc.description.sponsorshipUludag University [BUAP(F)-2014/3] This work was financially sponsored by Scientific and Technological Research Council of Turkey (grant number 113Z164) and Uludag University (project BUAP(F)-2014/3). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
dc.description.volume12
dc.identifier.doi10.2217/nnm-2017-0180
dc.identifier.eissn1748-6963
dc.identifier.issn1743-5889
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85030166267
dc.identifier.urihttps://doi.org/10.2217/nnm-2017-0180
dc.identifier.urihttps://hdl.handle.net/20.500.14288/16413
dc.identifier.wos411843400004
dc.keywordsAg2S quantum dots
dc.keywordsCancer therapy
dc.keywordsDoxorubicin
dc.keywordsNear-infrared imaging
dc.keywordsTargeting
dc.language.isoeng
dc.publisherFuture Medicine Ltd
dc.relation.ispartofNanomedicine
dc.subjectBiotechnology
dc.subjectApplied microbiology
dc.subjectNanoscience
dc.subjectNanotechnology
dc.titleFolic acid-conjugated cationic Ag2S quantum dots for optical imaging and selective doxorubicin delivery to HeLa cells
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorDuman, Fatma Demir
local.contributor.kuauthorKhodadust, Rouhollah
local.contributor.kuauthorAcar, Havva Funda Yağcı
local.publication.orgunit1GRADUATE SCHOOL OF SCIENCES AND ENGINEERING
local.publication.orgunit1College of Sciences
local.publication.orgunit1Research Center
local.publication.orgunit2Department of Chemistry
local.publication.orgunit2KUYTAM (Koç University Surface Science and Technology Center)
local.publication.orgunit2Graduate School of Sciences and Engineering
relation.isOrgUnitOfPublication035d8150-86c9-4107-af16-a6f0a4d538eb
relation.isOrgUnitOfPublication3fc31c89-e803-4eb1-af6b-6258bc42c3d8
relation.isOrgUnitOfPublicationd41f66ba-d7a4-4790-9f8f-a456c391209b
relation.isOrgUnitOfPublication.latestForDiscovery035d8150-86c9-4107-af16-a6f0a4d538eb
relation.isParentOrgUnitOfPublicationaf0395b0-7219-4165-a909-7016fa30932d
relation.isParentOrgUnitOfPublication434c9663-2b11-4e66-9399-c863e2ebae43
relation.isParentOrgUnitOfPublicationd437580f-9309-4ecb-864a-4af58309d287
relation.isParentOrgUnitOfPublication.latestForDiscoveryaf0395b0-7219-4165-a909-7016fa30932d

Files